Ballal Rahul D. 4
4 · Enliven Therapeutics, Inc. · Filed Oct 10, 2024
Insider Transaction Report
Form 4
Ballal Rahul D.
Director
Transactions
- Sale
Common Stock
2024-10-08$28.17/sh−10,420$293,557→ 22,341 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-08−4,106→ 12,322 totalExercise: $5.52Exp: 2032-01-28→ Common Stock (4,106 underlying) - Exercise/Conversion
Common Stock
2024-10-08$5.52/sh+4,106$22,665→ 32,761 total - Exercise/Conversion
Stock Option (right to buy)
2024-10-08−6,314→ 69,428 totalExercise: $19.68Exp: 2029-05-16→ Common Stock (6,314 underlying) - Exercise/Conversion
Common Stock
2024-10-08$19.68/sh+6,314$124,260→ 28,655 total
Footnotes (4)
- [F1]The option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 19, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $28.00 to $28.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- [F4]The option, originally for 32,849 shares, vested as to one-fourth of the shares on January 28, 2023, and the remainder of the shares vest in 12 equal quarterly installments thereafter.